Vaxcyte, Inc.
Vaxcyte (PCVX) accelerated its Phase 3 OPUS-1 trial data release to October, adding Pfizer's Luis Jodar and Teva's David McAvoy to its leadership. The trial compares VAX-31 against Prevnar 20 and Capvaxive, with results critical for Vaxcyte's market entry. The company has $2.5B in cash and no approved products yet.
Vaxcyte's EVP Jim Wassil sold 2,715 shares for $163,862 between September 4-9, 2026, at prices ranging $59.155-$61.57. He also surrendered 5,459 shares to cover tax obligations. Vaxcyte's stock is up 82% over the past year, trading at $59.51. The company announced leadership changes and updated its VAX-31 vaccine trial data timeline to October 2026.
Vaxcyte officer James Wassil filed a Form 144 to sell 1,334 shares worth $80,026.66, following an RSU vest on September 7, 2026. Recent sales include 9,308 shares over three months, all executed through a broker.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning PCVX (Vaxcyte, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent PCVX coverage spans financial news, technology and earnings.
In the last 30 days, PCVX insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($376K). The most active reporter was Wassil Jim, CHIEF OPERATING OFFICER, with 4 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The leadership additions signal preparation for a potential launch, while the earlier data date creates a near‑term price catalyst.
Small insider sell may signal limited confidence but size is modest.
Minor insider sell of $80k may signal personal liquidity need but unlikely to affect market price.
The small insider disposition is unlikely to move the stock price materially.
The upcoming data release could drive significant price movement depending on trial outcomes.
AlphAI scores every news story that mentions PCVX with an AI model for sentiment and relevance, and aggregates insider trades from Vaxcyte, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Vaxcyte (PCVX) accelerated its Phase 3 OPUS-1 trial data release to October, adding Pfizer's Luis Jodar and Teva's David McAvoy to its leadership. The trial compares VAX-31 against Prevnar 20 and Capvaxive, with results critical for Vaxcyte's market entry. The company has $2.5B in cash and no approved products yet.
2 min readVaxcyte's EVP Jim Wassil sold 2,715 shares for $163,862 between September 4-9, 2026, at prices ranging $59.155-$61.57. He also surrendered 5,459 shares to cover tax obligations. Vaxcyte's stock is up 82% over the past year, trading at $59.51. The company announced leadership changes and updated its VAX-31 vaccine trial data timeline to October 2026.
1 min readVaxcyte officer James Wassil filed a Form 144 to sell 1,334 shares worth $80,026.66, following an RSU vest on September 7, 2026. Recent sales include 9,308 shares over three months, all executed through a broker.
1 min readVaxcyte's CFO Andrew Guggenhime disposed of 2,705 shares to meet tax obligations, retaining 164,000 shares worth $10.12M. Vaxcyte, a clinical-stage biotech, has a $9B market cap and 95% one-year share price growth. Its lead vaccine candidate, VAX-24, is in clinical trials.
2 min readVaxcyte Inc (PCVX) announced it will release topline Phase 3 trial results for its pneumococcal vaccine candidate VAX-31 by the end of October 2026. The company also appointed new executives. PCVX has no current revenue, but its stock price has risen nearly 90% over the past year. The company's GF Score is 34/100, reflecting strong momentum but weak profitability and modest financial strength. Insiders have sold $8.9 million in shares over the past 12 months.
2 min readVaxcyte (PCVX) reported a near-doubled net loss of $284.3M in Q2, with key Phase 3 trial results for its pneumococcal vaccine candidate VAX-31 expected by late 2026. The company has $2.5B in cash and added vaccine industry veterans to its board. Success hinges on upcoming clinical data.
3 min readVaxcyte (PCVX) appointed Luis Jodar as Chief Medical Officer and David McAvoy as Chief Legal Officer. The company expects Phase 3 trial data for VAX-31 by October, earlier than previously guided. PCVX stock closed at $61.17, down 0.67%, and is down 1.24% in after-hours trading.
1 min readVaxcyte, Inc. (PCVX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data Luis Jodar, Ph.D., Former Pfizer Chief Medical Officer for Vaccines and Infectious Diseases with Extensive Leadership Experience Across Clinical Development an
1 min readBaupost Group, via its 13F filed Aug. 13, 2026, reported exiting all of its Vaxcyte (PCVX) shares during the June quarter, cutting 800,000 shares to zero, a reported -$46.5M change. It also exited Willis Towers Watson (WTW), reducing 893,126 shares to zero, -$259.6M. The article cites Vaxcyte’s pre-revenue status and upcoming OPUS-1 Phase 3 topline in Q4 2026.
6 min readMizuho updated its U.S. healthcare “Top Picks” list for 2026, citing seven companies across biotech, medical devices, and healthcare services. Highlights include Eyepoint Pharmaceuticals (Duravyu Phase 3 data expected Aug 2026), Vaxcyte (PCV Phase 3 OPUS-1 data in Q4 2026), Erasca (raised about $632.5M in an offering), and Arcutis (Zoryve guidance $480M-$495M for 2026).
5 min read
